Monday, 18 October 2021

Major Indian Hospital Cancel Sputnik V orders

Major Indian Hospital Cancel Sputnik V orders

Many private hospitals in India have canceled the order for the Sputnik V vaccine as they struggle to sell COVID-19 jab amid surging supplies of free doses of other vaccines offering by the government of India.

Officials of some industries said low demand and the freezing storage temperatures required had moved at least three major hospitals to cancel an order for the Sputnik V vaccine, sold only to the private market to the world's biggest vaccine producer.

Jitendra Oswal, a senior medical official, said

"With storage and everything, we have cancelled the order for 2,500 dosage,"

"Demand is also not much. There is a class of people, only 1%, that wanted to go for Sputnik vaccine."

From May to last week, private hospitals assigned out just about 6% of all vaccines administered in India. However, the government had freed them to buy up to a quarter of domestic output, Health Ministry data shows.

Indian Major Hospital Cancel Sputnik V orders 1unsplash image

Read More : Covishield, Sputnik V cost cheaper than Covaxin

India is a major production center of Sputnik V, with a planned capacity of about 850 million shots a year. Low domestic uptake could mean higher exports. Instead, step backers are already pushing.

Since the June launch event by Indian distributor Dr. Reddy's Laboratories Ltd, only 943,000 Sputnik V doses have been delivered by hospitals,

The mainstay of India's vaccination drive is the AstraZeneca vaccines, which can be stored in regular cold storage. Unlike Sputnik V, vaccine which needs temperatures of -18 degrees Celsius (-0.4 degrees Fahrenheit), it's impossible to assure in most areas in the India region.

The Sputnik vaccine is also 47% more expensive than the AstraZeneca vaccine on the private market.

Sputnik V vaccine is just one of the vaccines suffering from a sharp drop in sales in the private market. Pune's Bharati Hospital will end its COVID-19 vaccination program when it runs out of AstraZeneca doses, as daily inoculations have fallen about 90% to 100 since private sales picked up in May and June, Oswal said.

Just 9,000 doses remain of stocks of 62,000 it ordered. The source said Avis's COVID-19 vaccine sales had shrunk 40%, with existing stores expected to last until December instead of October.

India's monthly production of the vaccine, mainly of the AstraZeneca shot known domestically as Covishield, had quadrupled to 300 million doses from April, when a dramatic surge in infections and deaths prompted a halt in exports. Overseas sales are to resume in October.

Covishield accounts for 88% of India's vaccinations, followed by Bharat Biotech's domestically developed Covaxin, and both have been administered free, mainly at government centers, since mid-January.

Follow Us

Popular Post